Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-Bκ pathway

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1117-1122

  Tozawa, Keiichi ^a   Sagawa, Morihiko ^b   Kizaki, Masahiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Celastrol; Multiple myeloma; Nuclear factor B (NF B)

Indexed keywords

CASPASE 3; CELASTROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MEMBRANE POTENTIAL; MITOCHONDRIAL TRANSMEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MITOCHONDRIA; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 80053192325     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1161     Document Type: Article

References (36)

1. Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937, 2002. (Pubitemid 37328894)
2. Weber D: Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 10: 375-383, 2003.
3. Laubach JP, Mahindra A, Richardson PG, et al: The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23: 2222-2232, 2009.
4. Chauhan D, Hideshima T, Mitsiades C, Richardson P and Anderson KC: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4: 686-692, 2005. (Pubitemid 40601851)
5. Miyakoshi S, Kami M, Oshimi K, et al: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107: 3492-3494, 2006.
6. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M and Kiernan MC: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15: 3081-3094, 2008.
7. Anderson KC: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35 (Suppl 1): S155-S162, 2007.
8. Chanan-Khan AA, Borrello I, Lee KP and Deece DE: Development of target-specific treatments in multiple myeloma. Br J Haematol 151: 3-15, 2010.
9. Jin HZ, Hwang BY, Kim HS, Lee JH, Kim YH and Lee JJ: Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-κB activation and NO production. J Nat Prod 65: 89-91, 2002.
10. Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y and Muller CD: Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 322: 778-786, 2004. (Pubitemid 39164421)
11. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA and Vigo C: Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25: 1341-1357, 2001. (Pubitemid 33022713)
12. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y and Sakato N: Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67: 1883-1887, 2003. (Pubitemid 39251707)
13. Yang H, Chen D, Cui QC, Yuan X and Dou QP: Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine', is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765, 2006.
14. Baldwin AS Jr: The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
15. Ghost S, Mary MJ and Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998.
16. Palumbo A and Rajkumar SV: Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 84: 379-390, 2010.
17. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008.
18. Ludwig H, Beksac M, Blade J, et al: Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15: 6-25, 2010.
19. Chanan-Khan AA and Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 1-13, 2010.
20. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999. (Pubitemid 29077388)
21. Zhang B, Potyagaylo V and Fenton RG: IL-6-independent expression of Mcl-1 in human multiple myeloma. Oncogene 22: 1848-1859, 2003. (Pubitemid 36513143)
22. Mann J: Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2: 143-148, 2002.
23. Simmons TL, Andrianasolo E, McPhail K, Flatt P and Gerwick WH: Marine natural products as anticancer drugs. Mol Cancer Ther 4: 333-342, 2005. (Pubitemid 40340212)
24. Ito K, Nakazato T, Kizaki M, et al: 1'-acetoxychavicol acetate is a novel nuclear factor kappa B inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65: 4417-4424, 2005. (Pubitemid 40775681)
25. Nakazato T, Ito K, Kizaki M, et al: Catechin, a green tea component, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo. Haematologica 90: 317-325, 2005. (Pubitemid 40388981)
26. Nakazato T, Ito K, Ikeda Y and Kizaki M: Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res 11: 6040-6049, 2005. (Pubitemid 41170336)
27. Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y and Kizaki M: Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol 71: 742-750, 2006. (Pubitemid 43208830)
28. Xian M, Ito K, Kizaki M, et al: Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway. Cancer Sci 98: 118-126, 2007. (Pubitemid 44803930)
29. Muto A, Hori M, Yoshida T, et al: Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6: 987-994, 2007. (Pubitemid 46554568)
30. Sagawa M, Nakazato T, Uchida H, Ikeda Y and Kizaki M: Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci 99: 1820-1826, 2008.
31. Lu Z, Jin Y, Qiu L, Lai Y and Pan J: Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett 290: 182-191, 2010.
32. Sung B, Park B, Yadav VR and Aggarwal BB: Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the downregulation of cell survival proteins and upregulation of death receptors. J Biol Chem 285: 11498-11507, 2010.
33. Garg A and Aggarwal BB: Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 16: 1053-1068, 2002. (Pubitemid 34618844)
34. Lee CH, Jeon YT, Kim SH and Song YS: NF-κB as a potential molecular target for cancer therapy. Biofactors 29: 19-35, 2007. (Pubitemid 46985299)
35. Chadli A, Felts SJ, Mer G, et al: Celastrol inhibits Hsp90 chaperoning of steroid receptors by inducing fibrillization of the Co-chaperone p23. J Biol Chem 285: 4224-4231, 2010.
36. Zhang T, Li Y, Yu Y, Zou P, Jiang Y and Sun D: Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 284: 35381-35389, 2009.